Table 2.

Reclassification according to prognosis

	Histological diagnosis	Total	LTS	STS
Original histological diagnosis (n = 385)	Astrocytic, WHO grade II	104	88 (84.6%)	16 (15.4%)
	Astrocytic, WHO grade III	99	42 (42.4%)	57 (57.6%)
	Mixed (oligoastrocytic), WHO grade II	64	61 (95.3%)	3 (4.7%)
	Mixed (oligoastrocytic), WHO grade III	22	17 (77.3%)	5 (22.7%)
	Oligodendroglioma, WHO grade II	60	58 (96.7%)	2 (3.3%)
	Oligodendroglioma, WHO grade III	34	28 (82.4%)	6 (17.6%)
	Glioma, NOS	2	–	2 (100.0%)
WHO 2016 (n = 325)	Diffuse astrocytoma, IDH-mutant, WHO grade II	97	93 (95.9%)	4 (4.1%)
	Anaplastic astrocytoma, IDH-mutant, WHO grade III	36	34 (94.4%)	2 (5.6%)
	Oligodendroglioma, IDH-mutant, 1p/19q-codeleted, WHO grade II	80	79 (98.8%)	1 (1.3%)
	Anaplastic oligodendroglioma, IDH-mutant, 1p/19q-codeleted, WHO grade III	37	34 (91.9%)	3 (8.1%)
	Diffuse astrocytoma, IDH-wildtype, WHO grade II	18	4 (22.2%)	14 (77.8%)
	Anaplastic astrocytoma, IDH-wildtype, WHO grade III	52	1 (1.9%)	51 (98.1%)
	Diffuse midline glioma, H3K27-mutant, WHO grade IV	2	–	2 (100.0%)
	Anaplastic pilocytic astrocytoma, WHO grade III	2	–	2 (100.0%)
	Dysembryoplastic neuroepithelial tumor, WHO grade I	1	1 (100.0%)	-
WHO 2021 (n = 258)	Astrocytoma, IDH-mutant, CNS WHO grade 2	66	64 (97.0%)	2 (3.0%)
	Astrocytoma, IDH-mutant, CNS WHO grade 3	24	24 (100.0%)	–
	Astrocytoma, IDH-mutant, CNS WHO grade 4	3	3 (100.0%)	–
	Oligodendroglioma, IDH-mutant, 1p/19q-codeleted, CNS WHO grade 2	80	79 (98.8%)	1 (1.2%)
	Oligodendroglioma, IDH-mutant, 1p/19q-codeleted, CNS WHO grade 3	37	34 (91.9%)	3 (8.1%)
	Glioblastoma, IDH-wildtype, CNS WHO grade 4	42	3 (7.1%)	39 (92.9%)
	Diffuse midline glioma, H3K27-altered, CNS WHO grade 4	2	–	2 (100.0%)
	High-grade astrocytoma with piloid features, CNS WHO grade 3	3	–	3 (100.0%)
	Dysembryoplastic neuroepithelial tumor, CNS WHO grade 1	1	1 (100.0%)	–

CNS = Central Nervous System; IDH = isocitrate dehydrogenase; LTS = long-term survivors; NOS = not otherwise specified; STS = short-term survivors; WHO = World Health Organization